Drug Database
NI

nifedipine

✓ Approved

Adare Pharma Solutions · CACNA1C · 小分子

什么是 nifedipine?

nifedipine 是一种小分子,由Adare Pharma Solutions研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

公司Adare Pharma Solutions
药物类别小分子
分子靶点CACNA1C
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

nifedipine 作用于 1 个分子靶点:

CACNA1Ccalcium voltage-gated channel subunit alpha1 C (CACNL1A1, CACNA1C-IT2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

nifedipine 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Cardiac disordersAngina pectoris✓ Approved
Vascular disordersHypertension✓ Approved

相关研究文献

PubMedJournal of medical case reports2026-11-13

Multiple co-occurring genetic variants in an elderly patient with Liddle's-like syndrome: a case report and literature review.

Liang Yunlong Y, Zheng YangZhi Y, Yuan Hua H, Guo Li L et al.

Liddle syndrome (LS) is a rare autosomal dominant condition classically defined by early-onset hypertension, hypokalemia, metabolic alkalosis, and a suppressed renin-aldosterone profile, primarily driven by gain-of-function mutations in the SCNN1A, SCNN1B, or SCNN1G genes encoding the epithelial sodium channel (ENaC). Nevertheless, genetically investigated cases exhibiting Liddle's-like phenotypes in the elderly population remain exceptionally rare. We report a 61-year-old male admitted with recurrent limb weakness and resistant hypertension. A comprehensive clinical workup, including biochemical profiles, RAAS evaluation, and 24-h ABPM, was conducted to exclude common secondary causes. Following informed consent, whole-exome sequencing (WES) was performed, with candidate variants validated by Sanger sequencing and assessed per ACMG/AMP guidelines. To guide therapeutic management, a narrative literature review of similar cases was also performed searching PubMed, Web of Science, and CNKI using keywords like "Liddle syndrome," "elderly," "hypertension," and "hypokalemia.". Admission tests showed hypokalemia (2.94 mmol/L), compensated metabolic alkalosis, and suppressed renin-aldosterone levels. 24-h ABPM indicated severe blood pressure fluctuations up to 185/120 mmHg. Genetic testing revealed three heterozygous variants of uncertain significance (VUS)-CYP3A5 (c.1253 + 83C > T), SCNN1G (c.1727A > G, p.Lys576Arg), and WNK1 (c.5636A > T, p.Asp1879Val)-without any known pathogenic variants. A diagnostic trial with triamterene (50 mg twice daily) restored normal potassium levels (> 3.5 mmol/L). After a 30-day combination therapy of controlled-release nifedipine and irbesartan, blood pressure stabilized between 110 and 133 and 69-85 mmHg. We report an elderly patient with chronic hypokalemia and resistant hypertension. After ruling out common secondary causes (for example, primary aldosteronism, Cushing's syndrome, pheochromocytoma), Liddle's-like syndrome was clinically diagnosed based on the low-renin/low-aldosterone biochemical phenotype, compensated metabolic alkalosis, literature review, and a selective response to triamterene. This case suggests that Liddle's-like syndrome must be considered in the differential diagnosis of hypokalemic hypertension in older adults to ensure early and targeted therapy.

PMID 43021310
阅读全文 →
PubMedJournal of the Endocrine Society2026-11-12

Aortic dilatation and gastrointestinal disease: expansion of the hyperinsulinism-polycystic kidney disease phenotype.

Yau Daphne D, Diaz-Moreno Unai U, Cervi Elena E, Shaunak Meera M et al.

Congenital hyperinsulinism (HI) with polycystic kidney disease (PKD), or HIPKD, is a recently described syndrome caused by a specific promotor variant in PMM2, a gene otherwise associated with PMM2 congenital disorder of glycosylation. To describe the HIPKD clinical phenotype, expanding our understanding and its distinction from the congenital disorder of glycosylation phenotype. Retrospective multicenter cohort study of individuals with HIPKD identified through an international HI genetic referral center. Ten individuals from 9 families compound heterozygous for the promoter variant c.-167G > T and a pathogenic intragenic variant in PMM2. None. Observed clinical features and outcomes. Median age of presentation was 5 months (range 0-42). Median age at follow up was 12.7 years (range 5.4-20.1). HI was managed with diazoxide monotherapy (7/10 patients), diazoxide and nifedipine (2/10 patients), and carbohydrate supplementation alone (1/10 patient). PKD age at diagnosis and severity was variable, ranging from antenatal presentation requiring renal transplantation, to incidental detection in mid-childhood. Liver cysts were noted in 6/10 patients (5/6 with normal liver function). Five of 7 patients had systemic hypertension and 3/5 were normotensive on losartan at last follow up. Inflammatory bowel disease (IBD) with gastric antral foveolar hyperplasia occurred in 4/10 patients, and aortic root and/or ascending aortic dilation in 4/7 patients who underwent echocardiography, 3 of whom also had IBD. HIPKD due to a PMM2 promoter variant is associated with broad, multisystem phenotype, including IBD and aortic dilation. These findings support targeted screening for IBD and cardiovascular surveillance in addition to standard endocrine and renal follow up.

PMID 43016986
阅读全文 →
PubMedReproductive sciences (Thousand Oaks, Calif.)2026-11-11

The Effect of Nifedipine and NS11021 on the Human Umbilical Artery and Myometrium in Pregnancies Complicated by Intrahepatic Cholestasis.

Uysal Nusret N, Acar-Sahan Selin S, Sengul Mustafa M, Simsek Fatma F et al.

The aim of this study was to investigate the functional responses of umbilical arteries and myometrial smooth muscle tissue from pregnant women with intrahepatic cholestasis and healthy pregnant women to the calcium channel blocker nifedipine and the K⁺ channel opener NS11021, and to evaluate histopathological findings. Umbilical arteries and myometrium were isolated immediately after delivery from 8 healthy and 7 cholestatic pregnant women, and smooth muscle responses to nifedipine (10⁻8-10⁻5 M) and NS11021 (10⁻8-10⁻6 M) were examined in isolated organ baths. Histopathological and immunohistochemical investigations were also performed. In the cholestasis group, the maximum response and sensitivity to nifedipine and NS11021 in the myometrium were not altered, whereas in the umbilical artery, sensitivity to nifedipine decreased, and both maximum response and sensitivity to NS11021 decreased. Histological examinations demonstrated increased apoptosis in the umbilical artery and myometrium. These findings suggest that intrahepatic cholestasis of pregnancy may be associated with more pronounced alterations in pharmacological responses to nifedipine and NS11021 in the umbilical artery than in the myometrium, which may contribute to fetal complications. Further controlled studies are needed to clarify the pathophysiology of intrahepatic cholestasis of pregnancy and related fetal outcomes.

PMID 43013200
阅读全文 →
PubMedThe journal of obstetrics and gynaecology research2026-11-10

Hemodynamic Effects of Controlled-Release Nifedipine for Tocolysis in Normotensive Pregnant Women.

Ushida Takafumi T, Fujito Sumire S, Shiraishi Yoshitaka Y, Nozaki Yuki Y et al.

Nifedipine is widely used as a tocolytic agent for threatened preterm labor. However, its hemodynamic effects in normotensive pregnant women, particularly when administered as a controlled-release formulation, remain unclear. We evaluated changes in maternal hemodynamics and adverse effects after controlled-release nifedipine administration in normotensive pregnant women with threatened preterm labor. This retrospective observational study included normotensive women with singleton pregnancies who received controlled-release nifedipine as maintenance therapy for threatened preterm labor between 2018 and 2025. Maternal blood pressure, heart rate, respiratory rate, hypotension (systolic blood pressure < 90 mmHg or diastolic blood pressure < 60 mmHg), tachycardia (≥ 120 beats/min), and adverse maternal and fetal effects were evaluated before and after nifedipine administration. Overall, 38 women were included in the final analyses. Systolic blood pressure significantly decreased from 110.2 ± 9.1 mmHg to 107.5 ± 10.2 mmHg after administration (mean change, -2.7 mmHg; 95% confidence interval, -4.5 to -0.8; p < 0.01). Diastolic blood pressure did not change significantly (-0.7 mmHg; -2.2 to 0.8 mmHg; p = 0.35). Heart rate significantly decreased from 95.3 ± 14.5 to 90.9 ± 12.4 beats/min. The incidence of hypotension and tachycardia did not differ significantly after nifedipine administration. No emergency deliveries were attributed to maternal hypotension. Headache was the most commonly reported adverse effect (28.9%). Controlled-release nifedipine was associated with a small decrease in systolic blood pressure without serious maternal or fetal adverse events. With appropriate monitoring, controlled-release nifedipine may be a feasible option for maintenance or adjunctive tocolytic therapy in normotensive pregnant women.

PMID 43006657
阅读全文 →
PubMedFrontiers in pharmacology2026-11-08

Engineered hyalurosomal gel co-delivering citicoline sodium and nifedipine for potential glaucoma management: formulation and pharmacodynamic evaluation.

Hegazy Doaa D, Ibrahim Mennatullah M MM, El-Shiekh Riham A RA, Saher Osama O et al.

Glaucoma is a neurodegenerative ocular disorder that requires multi-targeted therapeutic strategies to counteract intraocular pressure (IOP) elevation and oxidative stress-mediated retinal ganglion cells (RGCs) loss. This study developed an innovative hyalurosomal hydrogel platform co-delivering Nifedipine (NFD, a calcium channel blocker that promotes ocular vasodilation and IOP reduction) and Citicoline sodium (CTC, a potent neuroprotective and antioxidant agent) as a potential topical therapeutic approach for glaucoma. NFD-loaded hyalurosomes (NFD-HAs) were prepared using thin-film hydration and statistically optimized via a D-Optimal design. The optimized formulation (NFD-OF) was probe-sonicated, combined with CTC, and incorporated into an HPMC hydrogel. Sonicated NFD-OF displayed nanosized spherical vesicles (198.6 ± 23.1 nm), high entrapment efficiency (70.7 ± 1.8%), and stable zeta potential (-39.1 ± 1.3 mV). Transmission electron microscopy (TEM) analysis confirmed the distinct spherical morphology, non-aggregated state, and structural integrity of NFD-OF. The final CTC/NFD-OF gel exhibited pseudoplastic shear-thinning flow, an optimal ocular pH (6.9 ± 0.02), and sustained release over 24 h (65.5% for NFD and 99.5% for CTC). The dual gel demonstrated superior free radical scavenging capability (IC50 = 16.44±0.7 μg/mL) compared to free NFD (219.43 μg/mL) and CTC (234.62 μg/mL). Confocal microscopy confirmed a 2.2-fold enhancement in transcorneal penetration depth (110 μm) compared with the control solution (50 μm). In vivo pharmacodynamic evaluation revealed a significantly higher maximum IOP decrease (51.85 ± 8.2%), extended mean residence time (8.9 ± 2.7 h), and increased relative exposure (AUC0-∞ = 494.1 ± 191.9) compared to commercial Xola™ eye drops (36.4 ± 5.9% max IOP decrease, AUC0-∞ = 182.8 ± 33.7). Terminal gamma sterilization preserved physicochemical characteristics and release profiles. Draize and histopathological assays confirmed excellent ocular tolerability. Overall, the CTC/NFD-OF gel demonstrated promising ocular hypotensive activity and safety, supporting its potential as a multifunctional topical therapeutic approach for glaucoma.

PMID 42996362
阅读全文 →
PubMedRSC advances2026-11-04

Drug-drug adsorption-based miniaturized solid phase extraction of amlodipine from biological samples before HPLC-PDA analysis.

Mohammadmehri Sina S, Farajzadeh Mir Ali MA, Khoubnasabjafari Maryam M, Shahedi Hojghan Ali A et al.

A nifedipine-assisted miniaturized solid phase extraction coupled with high-performance liquid chromatography-photodiode array method was developed for the extraction and quantification of amlodipine in biological samples. The extraction process was optimized by evaluating the influence of key parameters, including nifedipine amount, agitation mode and time, aqueous phase pH, salt addition, and desorption solvent conditions. Optimal performance was obtained using 7 mg of nifedipine, vortex agitation for 3 min, pH 9, without salt addition, and using ethanol (175 µL) as the desorption solvent. Under these conditions, the method showed good analytical sensitivity, with limits of detection and quantification of 0.54 and 1.7 µg L-1 in deionized water; 2.2 and 6.8 µg L-1 in plasma; and 1.9 and 6.3 µg L-1 in urine, respectively. A linear response was observed over the concentration range of 6.8-200 µg L-1 in plasma, with a correlation coefficient 0.998. The method demonstrated acceptable precision, with relative standard deviation values below 8%, and an extraction recovery of 68 ± 4%. The applicability of the developed method was confirmed through analysis of spiked plasma and urine samples at the concentration levels of 10, 25, and 50 µg L-1. The relative recovery values ranged between 88% and 96% and indicated negligible matrix effects, which confirms the suitability of the method for reliable determination of amlodipine in biological matrices.

PMID 42979374
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多nifedipine